Mitsubishi Tanabe's sales static, but recall impact to be limited
This article was originally published in Scrip
Amid a swirl of controversy over a major recall of products in its home market, Japan's Mitsubishi Tanabe Pharma (MTP) has reported static sales in the nine months to 31 December.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.